ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2021-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Irinotecan (Camptosar) in Patients With Advanced Sarcomas

NCT00509860

Sarcoma

COMPLETED PHASE2

Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

NCT01710176

Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults

COMPLETED PHASE3

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

NCT03880019

Stage III Uterine Corpus Leiomyosarcoma AJCC v8 Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 Uterine Corpus Leiomyosarcoma

ACTIVE_NOT_RECRUITING PHASE2

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

NCT00822848

Sarcoma

COMPLETED PHASE1

Irinotecan and Temozolomide for Ewing Sarcoma

NCT03359005

Ewing Sarcoma

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ewing Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

niraparib and temozolomide

Niraparib (capsule) and temozolomide (capsule) will be taken together.

Group Type EXPERIMENTAL

niraparib

Intervention Type DRUG

Temozolomide

Intervention Type DRUG

niraparib and irinotecan

Niraparib will be taken orally and irinotecan will be administered intravenously.

Group Type EXPERIMENTAL

niraparib

Intervention Type DRUG

Irinotecan

Intervention Type DRUG

niraparib, irinotecan and temozolomide

Niraparib and temozolomide will be taken orally. Irinotecan will be administered intravenously.

Group Type EXPERIMENTAL

niraparib

Intervention Type DRUG

Temozolomide

Intervention Type DRUG

Irinotecan

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

niraparib

Intervention Type DRUG

Temozolomide

Intervention Type DRUG

Irinotecan

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed Ewing sarcoma
* Evidence of Ewing sarcoma translocation by FISH or RT-PCR.
* Must be willing to undergo tumor biopsy at study entry for biologic correlates.
* If patient \> 18 years, must be willing to undergo on-treatment tumor biopsy unless medically contra-indicated
* Recurrent or refractory tumors with no known curative treatment options according to the judgment of the investigator.
* Age ≥ 13 years.
* Life expectancy of ≥ 3 months.
* ECOG performance status 0-2.
* Measurable disease on CT or MRI by RECIST 1.1.
* Adequate organ function
* Patients must have received as a minimum a first line chemotherapy regimen consisting of at least 2 of the following agents: doxorubicin, cyclophosphamide, ifosfamide, etoposide.
* Time elapsed from previous therapy must be ≥ 3 weeks for systemic therapy, ≥ 2 weeks for radiation therapy or major surgery.
* Patients who have undergone autologous hematopoietic stem cell transplantation are eligible once they have recovered from all toxicities from therapy
* Patients who have received allogeneic hematopoietic stem cell transplantation will be eligible 6 months after the procedure provided there is no evidence of active graft-versus-host disease and immunosuppressive treatment has been discontinued for at least 30 days.
* Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of central nervous system metastatic disease, have been off glucocorticoids for at least 4 weeks, have no overt evidence of neurological deficit and are ≥ 6 weeks from completion of brain irradiation.
* Patients or their legal representative (if the patient is \< 18 years old) must be able to read, understand and provide written informed consent to participate in the trial.
* Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication.

Exclusion Criteria

* Clinically significant unrelated illness which would, in the judgment of the treating physician, compromise the patient's ability to tolerate the investigational agent or be likely to interfere with the study procedures or results.
* Patients with baseline QTc \> 480 msec.
* Inability to swallow capsules.
* Known hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs.
* Known hypersensitivity reaction to temozolomide or any of its components, or dacarbazine (DTIC) if enrolled on ARM 1 or irinotecan or any of its components if enrolled on ARM 2
* Concomitant use of any other investigational or anticancer agent(s).
* Pregnant patients or patients who are breast feeding. Subjects capable of pregnancy (post menarche and not post-menopausal, defined as over 12 months since final menstrual period) must have a negative pregnancy test within 7 days prior to first dose.
* Other clinically significant malignant disease diagnosed within the previous 5 years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer.
* Active central nervous system disease.
* Known history of MDS or AML
* Known persistent (\> 4 weeks) ≥ Grade 2 neutropenia, ≥ Grade 2 thrombocytopenia or \> Grade 3 anemia from prior cancer therapy

Minimum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No